Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

07-11-2021 | ACR 2021 | Conference coverage | Video

Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?

Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis (5.10).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

06-11-2021 | ACR 2021 | Conference coverage | News

KEEPsAKE trials show benefits of risankizumab in patients with PsA

04-06-2021 | EULAR 2021 | Conference coverage | Video

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial

04-06-2021 | EULAR 2021 | Conference coverage | News

KEEPsAKE 2 supports risankizumab for the treatment of PsA

20-10-2021 | Psoriatic arthritis | News

EMA recommends expanding risankizumab indication to include PsA
Image Credits